MedPath

RYSTIGGO

RYSTIGGO

Approved
DIN Number

02556081

Drug Class

Human

Market Date

N/A

Company
HC

UCB Canada Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02556081
AIG Number0166605001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
L04AG16 ROZANOLIXIZUMAB
Product Specifications
Dosage FormSolution
Route of AdministrationSubcutaneous
AHFS Classification90:08.04
Health Canada Classification

ACTIVE INGREDIENTS (1)

ROZANOLIXIZUMABActive
Strength: 140 MG / ML
Monograph: ROZANOLIXIZUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.